

***ARID1A* gene mutation in ovarian and endometrial cancers (Review)**

TAKASHI TAKEDA, KOUJI BANNO, RYUICHIRO OKAWA, MEGUMI YANOKURA, MOITO IJIMA, HARUKO IRIE-KUNITOMI, KANAKO NAKAMURA, MIHO IIDA, MASATAKA ADACHI, KIYOKO UMENE, YUYA NOGAMI, KENTA MASUDA, YUSUKE KOBAYASHI, EIICHIRO TOMINAGA and DAISUKE AOKI

Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo 160-8582, Japan

Received August 15, 2015; Accepted October 13, 2015

DOI: 10.3892/or.2015.4421

Abstract. The AT-rich interacting domain-containing protein 1A gene (*ARID1A*) encodes ARID1A, a member of the SWI/SNF chromatin remodeling complex. Mutation of *ARID1A* induces changes in expression of multiple genes (*CDKN1A*, *SMAD3*, *MLH1* and *PIK3IP1*) via chromatin remodeling dysfunction, contributes to carcinogenesis, and has been shown to cause transformation of cells in association with the PI3K/AKT pathway. Information on *ARID1A* has emerged from comprehensive genome-wide analyses with next-generation sequencers. *ARID1A* mutations have been found in various types of cancer and occur at high frequency in endometriosis-associated ovarian cancer, including clear cell adenocarcinoma and endometrioid adenocarcinoma, and also occur at endometrial cancer especially in endometrioid adenocarcinoma. It has also been suggested that *ARID1A* mutation occurs at the early stage of canceration from endometriosis to endometriosis-associated carcinoma in ovarian cancer and also from atypical endometrial hyperplasia to endometrioid adenocarcinoma in endometrial cancer. Therefore, development of a screening method that can detect mutations of *ARID1A* and activation of the PI3K/AKT pathway might enable early diagnosis of endometriosis-associated ovarian cancers and endometrial cancers. Important results may also emerge from a current clinical trial examining a multidrug regimen of temsirolimus, a small molecule inhibitor of the PI3K/AKT pathway, for treatment of advanced ovarian clear cell adenocarcinoma with *ARID1A* mutation and PI3K/AKT pathway activation. Also administration of sorafenib, a multikinase inhibitor, can inhibit cancer proliferation with *PIK3CA* mutation and resis-

tance to mTOR inhibitors and GSK126, a molecular-targeted drug can inhibit proliferation of *ARID1A*-mutated ovarian clear cell adenocarcinoma cells by targeting and inhibiting EZH2. Further studies are needed to determine the mechanism of chromatin remodeling dysregulation initiated by *ARID1A* mutation, to develop methods for early diagnosis, to investigate new cancer therapy targeting *ARID1A*, and to examine the involvement of *ARID1A* mutations in development, survival and progression of cancer cells.

Contents

1. Introduction
2. What is *ARID1A*?
3. *ARID1A* mutation in ovarian cancers
4. *ARID1A* mutation in endometrial carcinomas
5. *ARID1A* in molecular-targeted therapy and as a prognostic marker
6. Conclusion

1. Introduction

Several mutations in genes encoding chromatin remodeling complexes have been found in recent years using comprehensive genome-wide analyses with next-generation sequencers. Chromatin remodeling is a molecular mechanism of regulation of gene expression levels based on changes to chromatin structure; that is, regulation of the interaction of proteins with double-stranded DNA by changing the nucleosome structure in an ATP-dependent manner. This mechanism has impacts on transcription, replication, repair, methylation, and recombination of DNA (1). Dysfunction in the mechanism is likely to contribute to carcinogenesis, and aberrations in chromatin remodeling have been found in approximately 10% of all human cancers (2). Chromatin remodeling complexes alter the structure of nucleosomes by local ATP-dependent sliding of nucleosomes or by modification of histones (3,4). In sliding, the loosened chromatin structures appear to facilitate binding of proteins to double-stranded DNA, while the mechanism

Correspondence to: Dr Kouji Banno, Department of Obstetrics and Gynecology, Keio University School of Medicine, Shinanomachi 35, Shinjuku-ku, Tokyo 160-8582, Japan
E-mail: kbanno@z7.keio.jp

Key words: *ARID1A*, chromatin remodeling, ovarian cancer, endometrial cancer, PI3K/AKT

of histone modification is unclear (3). Chromatin remodeling complexes are also predicted to be involved in regulation of higher-order chromatin structures.

There are several types of chromatin remodeling complexes, including the SWItch/sucrose non-fermentable (SWI/SNF) complex, imitation SWI (ISWI) complex, INO80 complex and chromodomain helicase DNA-binding protein (CHD) complex. The SWI/SNF complex is involved in activation or inhibition of transcription, and plays a crucial role in carcinogenesis. Isakoff *et al* showed that inactivation of *SNF5p* (*SNF5*) in murine fibroblasts leads to both increased and decreased expression of genes (5). *SNF5* encodes SNF5, a core member of the SWI/SNF complex, and these results suggest that the SWI/SNF complex is involved in activation and inhibition of transcription. Medina *et al* found that ectopic expression of *SWI/SNF related, matrix associated, actin dependent regulator of chromatin subfamily a, member 4* (*SMARCA4*) in *SMARCA4*-deficient cells altered expression of ~1% of all genes (6). *SMARCA4* encodes BRG1, which is also a core member of the SWI/SNF complex, and these findings suggest that the SWI/SNF complex induces changes in gene expression and may play a crucial role in carcinogenesis.

The SWI/SNF complex is composed of many subunits, including an ATP-dependent catalytic subunit and a core subunit that is involved in construction of the complex and contains ARID1A (7-11). In this review, we focus on the relationships of *ARID1A* mutations with ovarian and endometrial cancers, and we discuss the possible use of ARID1A as a molecular target in diagnosis and treatment.

2. What is *ARID1A*?

ARID1A is located on chromosome 1p36.11 and encodes ARID1A, a core member of the SWI/SNF complex (12). This complex plays a crucial role in carcinogenesis, and thus *ARID1A* is viewed as a cancer-inhibiting gene, of which mutation may be involved in onset and progression of several cancers. Next-generation sequencers have enabled genome-wide analyses, and mutation of *ARID1A* in ovarian clear cell carcinoma and ovarian endometrioid carcinoma was first reported in 2010. Since then, *ARID1A* mutations have been found in many human cancers and sarcomas, with mutation frequencies of 34% in renal clear cell carcinoma (13), 8-27% in stomach cancer (14-16), 13% in transitional cell carcinoma of the bladder (16), 9.1-15% in esophageal adenocarcinoma (17,18), 10-13% in hepatocellular carcinoma (19,20), 9% in esophageal carcinoma (21), 8% in lung adenocarcinoma (22), 8% in prostate cancer (14), 4-8% in pancreas cancer (14,23,24), 2-4% in breast cancer (14,25,26), 14-17% in Burkitt lymphoma (27,28), 6% in neuroblastoma (29) and 2% in medulloblastoma (14). *ARID1A* mutation is especially common in gynecologic cancer, with rates of 46-57% in ovarian clear cell adenocarcinoma (30,31), 30% in ovarian endometrioid adenocarcinoma (31) and 40% in uterine endometrioid adenocarcinoma (32) (Table I). Most of these *ARID1A* mutations are frameshift or nonsense mutations. There are two types of hotspot for mutations. One is the mutations around nuclear export signal sequence resulting in reduced nuclear export of ARID1A, and another is the mutations affecting interactions between ARID1A and the other SWI/SNF subunits disturbing the stability of the whole

Table I. Tumors with *ARID1A* mutations (13-32).

Tumor	Rate (%)
Ovarian clear cell carcinoma	46-57
Ovarian endometrioid carcinoma	30
Low-grade endometrioid carcinoma	40
Renal clear cell carcinoma	34
Gastric carcinoma	8-27
Transitional cell carcinoma of the bladder	13
Esophageal adenocarcinoma	9.1-15
Hepatocellular carcinoma	10-13
Esophageal carcinoma	9
Pulmonary adenocarcinoma	8
Prostate carcinoma	8
Pancreatic carcinoma	2-8
Breast carcinoma	2-4
Burkitt lymphoma	14-17
Neuroblastoma	6
Medulloblastoma	2

protein complex (33). Recent meta-analysis indicated that loss of ARID1A was associated with cancer-specific mortality and cancer recurrence (34).

Many reports have suggested that *ARID1A* mutation is involved in onset and progression of cancer. Guan *et al* found that suppression of wild-type *ARID1A* in ovarian cancer cells with *ARID1A* mutation was sufficient to inhibit cell proliferation and tumor growth in mice, whereas silencing of *ARID1A* in non-transformed epithelial cells enhanced cellular proliferation and tumorigenicity in mice (35). Similarly, Streppel *et al* found enhanced cell proliferation following *ARID1A* knock-down in esophageal adenocarcinoma cells, whereas increased *ARID1A* expression in *ARID1A*-deficient cells significantly inhibited cell proliferation (18). Moreover, Guan *et al* showed that *ARID1A* promotes formation of the SWI/SNF chromatin remodeling complex containing BRG1, and with p53 regulates transcription of downstream effectors, including proteins encoded by *cyclin-dependent kinase inhibitor 1A* (*CDKN1A*) and *SMAD family member 3* (*SMAD3*). *CDKN1A* encodes p21, which acts as a regulator of cell cycle progression in G1 phase (35). *SMAD3* encodes SMAD3, which acts on transforming growth factor β (TGF- β) and serves as a regulator of differentiation, migration, and adhesion of cells. Briefly, mutation of *ARID1A* inactivates ARID1A/BRG1/p53 complex and they silence the transcription of *CDKN1A* and *SMAD3*. Finally the mutation of *ARID1A* inactivates these downstream effectors and causes tumor growth.

3. *ARID1A* mutation in ovarian cancers

ARID1A mutations occur in ovarian cancers at high frequency, and a close association between endometriosis-associated ovarian cancer and *ARID1A* mutation has been suggested in multiple studies. *ARID1A* mutations are found in 46-57% of ovarian clear cell carcinomas (30,31)

and in 30% of ovarian endometrioid carcinomas (31), but not in ovarian high-grade serous adenocarcinomas or ovarian mucinous adenocarcinomas (31,32), which are both closely associated with endometriosis. Loss of ARID1A expression is more frequent in endometriosis-associated ovarian clear cell carcinomas compared to those that are non-endometriosis-associated (36), with loss of ARID1A in 61% of cystic ovarian clear cell carcinomas compared to 43% of adenofibromatous ovarian clear cell carcinomas (36). Ovarian clear cell carcinomas can be divided into subgroups of cystic and adenofibromatous carcinomas (37), and cystic ovarian clear cell carcinoma is more closely associated with endometriosis and has a better prognosis. Endometrioid tumors are also associated with loss of ARID1A expression, which occurs at rates of 33 and 13% in borderline malignant tumors of the mucinous endocervical and endometrioid types, respectively, but not in those of the mucinous intestinal epithelium or serous types (38).

Multiple reports also suggest that *ARID1A* mutation occurs at the early stage of canceration from endometriosis to ovarian cancer. Yamamoto *et al* found that locations of ovarian cancer and endometriosis were associated with loss of *ARID1A* protein expression; that is, among endometrial lesions adjacent to *ARID1A*-deficient ovarian carcinomas, 86-100% were *ARID1A*-deficient. In contrast, solitary endometriosis and endometriosis distant from *ARID1A*-deficient ovarian carcinomas retained *ARID1A* expression (36). Similarly, Ayhan *et al* found loss of *ARID1A* expression in endometrial epithelia adjacent to *ARID1A*-deficient clear cell adenocarcinomas and endometrioid adenocarcinomas, whereas endometriotic cyst epithelia distant from *ARID1A*-deficient ovarian carcinomas retained *ARID1A* expression (39). The mechanism of transformation from endometriosis to ovarian cancer is unclear; however, the microenvironment around the endometrium is likely to have abundant iron-induced free radicals, and repeated damage and repair due to these radicals may lead to malignant transformation (40,41).

Recent studies have shown that *ARID1A* mutation is involved in carcinogenesis through multiple mechanisms, including via the phosphatidylinositol-3-kinase (PI3K)/AKT pathway. Activation of this pathway stimulates several mechanisms that cause progression to cancer, including proliferation of cancer cells, inhibition of apoptosis of cancer cells. These processes occur mainly via activation of tyrosine kinase receptors and somatic mutation of specific components of signal transduction, including loss of *phosphatase and tensin homolog* (*PTEN*), a cancer-suppressor gene, and activation of mutation of *phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit α* (*PIK3CA*). *PTEN* dephosphorylates phosphatidylinositol-3-phosphate (PIP3) into phosphorylated phosphatidylinositol-2-phosphate (PIP2), and competitively inhibits the PI3K/AKT pathway. *PIK3CA* encodes p110 α , a catalytic subunit of PI3K. The mammalian target of rapamycin complex 1 (mTORC1), a major downstream effector activated by signaling of AKT, plays a central role in growth and proliferation of cells. To investigate the effect of *ARID1A* on the PI3K/AKT pathway, Guan *et al* produced and compared *ARID1A* knockout mice (n= 9) and *ARID1A/PTEN* double knockout mice (n=22). Of the *ARID1A/PTEN* double knockout mice, 60% developed




Figure 1. The PI3K/AKT pathway. Activation of receptor tyrosine kinase (RTK) leads to activation of KRAS and PI3K. KRAS also activates PI3K. PI3K phosphorylates PIP2 to PIP3, whereas PTEN dephosphorylates PIP3 to PIP2. PIP3 in turn activates AKT and then mTOR, which leads to stimulation of cell growth, proliferation and survival. KRAS also contributes to these processes through another pathway.

poorly differentiated ovarian carcinoma with intraperitoneal dissemination and development of ascites, and the other 40% showed hyperplasia of the ovarian surface epithelium. In contrast, *ARID1A* knockout mice did not develop discernable histopathological changes, which suggests that mutation of *ARID1A* alone does not cause development and progression of cancer, but that a combination of *ARID1A* inactivation and a PI3K/AKT pathway aberration is sufficient to initiate tumorigenesis (42). *PTEN* knockout mouse (loss of *PTEN* alone) is not sufficient to initiate ovarian or endometrial tumorigenesis. However, loss of *PTEN* appears to potentiate tumorigenesis in ovaries with mutations of other genes like *ARID1A* or *APC* (43). *PIK3CA* is mutated in 33-46% of ovarian clear cell adenocarcinomas (44,45) and Yamamoto *et al* found that *PIK3CA* is frequently mutated in endometrial epithelia adjacent to ovarian clear cell adenocarcinomas (45) and that *PIK3CA* mutation and loss of *ARID1A* expression occur simultaneously (36,46).

4. *ARID1A* mutation in endometrial carcinomas

ARID1A is mutated at high frequency in both ovarian cancers and endometrial carcinomas (32). Aberrations in the PI3K/AKT pathway are present in $\geq 80\%$ of uterine endometrioid adenocarcinomas (47). Endometrioid adenocarcinoma is a type I uterine endometrial carcinoma, and this type has frequent mutations in *KRAS*, *PTEN* and *PIK3CA* (48). *KRAS* mutation is involved in cell proliferation and activates growth factors and the PI3K/AKT pathway. Since *KRAS*, *PTEN* and *PIK3CA* play roles in regulation of the PI3K/AKT pathway, it is likely that uterine endometrioid adenocarcinomas have many gene mutations associated with this pathway (Fig. 1).

An association between loss of *ARID1A* protein expression and activation of the PI3K/AKT pathway has also been found in type I endometrial carcinomas. *ARID1A* mutations are present in 40% of low-grade endometrioid adenocarcinomas, and loss of *ARID1A* expression occurs in 26-29% of low-grade and 39% of high-grade endometrioid adenocarcinomas (32,49). Moreover, in a classification of endometrial

carcinomas based on mutations in 9 genes, including *ARID1A*, *PTEN*, *PIK3CA*, *KRAS*, *P53* and *BRAF*, *ARID1A* mutation was detected in 47% of low-grade endometrioid adenocarcinomas, 60% of high-grade endometrioid adenocarcinomas, 11% of serous adenocarcinomas, and 24% of carcinosarcomas (50). Mutations of *PTEN* and *PIK3CA* also frequently occur in uterine endometrial carcinomas with *ARID1A* mutation, and these mutations induce aberrant activation of PI3K, phosphorylation of AKT, and inhibition of cell survival and apoptosis (51).

Another characteristic of type I endometrial carcinomas is induction of microsatellite instability (MSI). The cause of MSI may be a defect in DNA mismatch repair function, and loss of *ARID1A* expression may be associated with MSI in uterine endometrioid adenocarcinomas. Bosse *et al* found a strong association between *ARID1A* loss and sporadic MSI, and concluded that *ARID1A* may be a causative gene for MSI through a role in epigenetic silencing of the *mutL homolog 1 (MLH1)* gene in endometrial cancer (52).

In addition to its role in cancer development, *ARID1A* may also have a crucial role in progression of cancer. In immunohistochemical staining of atypical endometrial hyperplasia and uterine endometrioid carcinomas with an anti-*ARID1A* antibody, Mao *et al* defined the lack of staining in focal tumor areas as 'clonal loss', whereas the absence of *ARID1A* immunoreactivity in almost all tumor cells was defined as 'complete loss'. Clonal loss occurred at rates of 16% in atypical endometrial hyperplasia, 24% in uterine low-grade endometrioid carcinomas and 9% in uterine high-grade endometrioid carcinomas, whereas the respective rates of complete loss were 0, 25 and 44% in these diseases (53). This suggests that loss of *ARID1A* expression plays important roles in the early phase of tumor development and progression.

Uterine endometrial clear cell carcinoma (UCCC) is a rare disease that accounts for <5% of all endometrial carcinomas. The genetic basis of UCCC is mostly unknown, but downregulation of *ARID1A* has been found in 14-22% of UCCC cases, with these rates being lower than those in ovarian clear cell carcinoma (54-57).

5. *ARID1A* in molecular-targeted therapy and as a prognostic marker

The apparent importance of *ARID1A* mutation at the early stage of carcinogenesis from endometriosis to ovarian cancers suggests that detection of *ARID1A* mutation may be useful for early diagnosis of endometriosis-associated ovarian cancers. Practical application of *ARID1A*-dependent early diagnosis requires understanding of the molecular mechanism underlying transformation to cancer, advances in methods for detection of *ARID1A* mutation, and epidemiological examination of the relationship between *ARID1A* mutation and carcinogenesis. Greater clarity on the mechanisms through which *ARID1A* mutation causes transformation via aberrant activation of the PI3K/AKT pathway is likely to contribute to development of more convenient markers, while improved detection of *ARID1A* mutations is required for low-cost use of convenient samples such as cyst aspirates. Frequent *ARID1A* mutation in ovarian cancers has been reported, but cancer




Figure 2. Effects of *ARID1A* mutation and anticancer agents on the PI3K/AKT pathway. *ARID1A* mutations frequently co-occur with mutations of *PTEN* and *PIK3CA*. *PTEN* mutation inactivates *PTEN* and *PIK3CA* mutation activates PI3K, which lead to stimulation of cell growth, proliferation and survival. Temsirolimus inhibits the PI3K/AKT/mTOR signaling pathway by binding to the mTORC1 complex (65). Sorafenib is a multikinase inhibitor that targets the mitogen-activated protein kinase (MAPK) pathway, and also inhibits vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR).

incidences in cases with *ARID1A* mutation have not been investigated. Efficient screening tests require high positive and negative predictive values (58), which will require epidemiological studies of the relationship between *ARID1A* mutation and carcinogenesis.

Improved understanding of the carcinogenetic mechanism of *ARID1A* mutation is also likely to facilitate development of new therapies using molecules targeted against the effects of the *ARID1A* mutation. Molecular targeted therapy for ovarian clear cell adenocarcinoma is currently being examined. Takano *et al* found that combination therapy with temsirolimus, an mTOR inhibitor, and trabectedin, a new anticancer drug, for recurrent ovarian clear cell adenocarcinomas showed efficacy in a subset of patients and caused only mild adverse reactions (59). *ARID1A* mutation induces aberrant activation of PI3K and phosphorylation of AKT, which then targets mTOR, and in turn mTOR affects cell division, cell death and angiogenesis, and is involved in proliferation of cancer cells. Trabectedin is an alkylating agent that modifies guanine bases in DNA (60,61), and combination therapy of temsirolimus and trabectedin for recurrent ovarian clear cell adenocarcinomas is currently under examination in a phase II clinical trial. At the case report level, administration of sorafenib, a multikinase inhibitor, resulted in partial remission in a patient with stage IIIc ovarian clear cell adenocarcinoma with *PIK3CA* mutation and resistance to mTOR inhibitors (62) (Fig. 2).

In many cases, the *ARID1A* mutation is a frameshift or nonsense mutation. Thus, an anticancer drug that can repair these mutations may have broader efficacy and fewer adverse reactions compared with those of current molecular targeted drugs. However, most current drugs solely inhibit molecules with aberrant expression in cancer cells, and those targeting gene mutations remain at the research level.

A novel treatment strategy directly targeting enhancer of zeste homolog 2 (EZH2) has recently been reported. EZH2 is often overexpressed in ovarian clear cell adenocarcinomas and

generates the lysine 27 trimethylation on histone H3. GSK126, a small molecule and highly selective inhibitor of EZH2 methyltransferase, dose-dependently decreases the level of H3K27Me3 in ovarian clear cell adenocarcinoma cells with loss of *ARID1A* expression and inhibits their growth (63). The effect of GSK126 is reduced when expression of *ARID1A* is restored in these cells. An association with PI3K-interacting protein 1 gene (*PIK3IP1*), a direct target of *ARID1A* and EZH2 that is also often mutated in ovarian clear cell adenocarcinoma with *ARID1A* mutations. Mutation of *ARID1A* is related to reduced expression of *PIK3IP1*, and administration of GSK126 or restoration of *ARID1A* expression led to increased expression of *PIK3IP1*. GSK126 suppresses EZH2, and thus has the opposite effect of *ARID1A* or EZH2. Both *ARID1A* and EZH2 act on *PIK3IP1*, but *ARID1A* is more dominant than EZH2. With *PIK3IP1* overexpression, *PIK3IP1* inhibits cell proliferation and induces apoptosis in ovarian clear cell adenocarcinomas. Thus, *ARID1A* or *EZH2* regulate expression of *PIK3IP1* and a high rate of mutation of these genes in ovarian clear cell adenocarcinoma enhances cell proliferation and anti-apoptotic effects. GSK126 is a molecular-targeted drug that should inhibit proliferation of *ARID1A*-mutated ovarian clear cell adenocarcinoma cells by targeting and inhibiting EZH2. In mice, GSK126 also affects peritoneal dissemination (63). In the present study, the number of tumors after treatment with GSK126 was significantly lower than that in untreated mice after *ARID1A*-mutated ovarian clear cell adenocarcinoma cells were injected into the abdominal cavity (63). Based on all of these findings, GSK126 is likely to be among the most efficient molecular-targeted drugs against ovarian clear cell adenocarcinoma with *ARID1A* mutations.

ARID1B, a homolog of *ARID1A*, is also a possible target in molecular-targeted therapy (64). Knockdown of *ARID1B* in wild-type cells did not impair expression of the SWI/SNF complex, but knockdown in cells with *ARID1A* mutation led to loss of SMARCA4, the main subunit of ATPase, and other subunits. That is, co-occurrence of *ARID1A* and *ARID1B* mutations may be required for carcinogenesis, and a study of 297 *ARID1A*-mutant primary cancer samples identified 30 (10.1%) that also contained *ARID1B* mutations, with this rate being significantly higher than that of 3% in primary cancer samples without *ARID1A* mutation. This finding suggests that molecular-targeted therapy against *ARID1A* and *ARID1B* may produce better therapeutic effects.

Associations between *ARID1A* expression and prognosis have recently been reported in stomach cancer, bladder cancer, bowel cancer, and renal cell cancer, which suggests that *ARID1A* expression may serve as a prognostic marker (65-68). Meta-analysis also confirmed loss of *ARID1A* is associated with cancer-specific mortality and cancer recurrence (34). However, this association has only rarely been reported in gynecologic cancers, including in a clinically advanced stage and with tumor progression in uterus endometrioid adenocarcinomas (53). Thus, the association of *ARID1A* and prognosis in UCCC remains uncertain (55-57).

On the contrary, in a study conducted between 2006 and 2011 in 46 patients with International Federation of Gynecology and Obstetrics (FIGO) stage (1988) III and IV epithelial ovarian cancers, Yokoyama *et al* found that the expression level of *ARID1A* was correlated with prognosis

after chemotherapy. Twelve patients with a significantly lower level of *ARID1A* expression did not achieve complete response (CR). Of 34 patients who achieved CR, 21 patients who subsequently relapsed had relatively low levels of *ARID1A* (69). In addition, shorter progression-free survival after chemotherapy was found in the 11 patients with complete loss of *ARID1A* expression compared to 35 patients with *ARID1A* expression (69). In 112 patients with ovarian clear cell adenocarcinoma, Itamochi *et al* found an association between *ARID1A* expression and prognosis, and a relationship between *ARID1A* expression and each FIGO (1988) stage (70). Thus, the 5-year survival rate for FIGO stage I or II patients with positive tumor expression of *ARID1A* was 91%, while that for patients with negative tumor expression of *ARID1A* was 74%. However, this difference was not observed in FIGO stages III or IV. Based on these findings, *ARID1A* may be a biomarker that is predictive of prognosis of patients with FIGO stage I and II ovarian clear cell adenocarcinoma (70).

6. Conclusion

Advances in comprehensive genome analysis have permitted identification of mutations in multiple genes encoding chromatin remodeling factors in human cancers. Genes encoding proteins making up the SWI/SNF chromatin remodeling complex have been found to have particularly inactivating mutations at high frequency, and this complex has been suggested to inhibit malignant transformation. One such gene is *ARID1A*, and *ARID1A* mutations that eliminate expression of *ARID1A* protein produce abnormalities in chromatin remodeling and contribute to canceration from endometriosis to endometriosis-associated ovarian cancers. Since chromatin remodeling is involved in regulation of expression of multiple genes and in genome instability, its dysregulation is likely to have multiphase and significant impacts on development, survival, and progression of endometriosis, but the detailed mechanisms remain unclear. Further studies are needed to determine the mechanism of chromatin remodeling dysregulation initiated by *ARID1A* mutation, to develop methods for early diagnosis via detection of *ARID1A*, to investigate new cancer therapy targeting *ARID1A*, and to examine the involvement of *ARID1A* mutations in development, survival and progression of cancer cells.

Acknowledgements

We thank Dr K. Kitagawa, Dr Y. Ohfuji and Dr M. Hayakawa for helpful assistance. The authors gratefully acknowledge grant support from the Medical Research Encouragement Prize of The Japan Medical Association and from the Keio Gijyuku Academic Development Fund. The funders had no role in data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Clapier CR and Cairns BR: The biology of chromatin remodeling complexes. *Annu Rev Biochem* 78: 273-304, 2009.
2. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr and Kinzler KW: Cancer genome landscapes. *Science* 339: 1546-1558, 2013.

3. Saha A, Wittmeyer J and Cairns BR: Chromatin remodelling: The industrial revolution of DNA around histones. *Nat Rev Mol Cell Biol* 7: 437-447, 2006.
4. Lorch Y, Maier-Davis B and Kornberg RD: Mechanism of chromatin remodeling. *Proc Natl Acad Sci USA* 107: 3458-3462, 2010.
5. Isakoff MS, Sansam CG, Tamayo P, Subramanian A, Evans JA, Fillmore CM, Wang X, Biegel JA, Pomeroy SL, Mesirov JP, *et al*: Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation. *Proc Natl Acad Sci USA* 102: 17745-17750, 2005.
6. Medina PP, Carretero J, Ballestar E, Angulo B, Lopez-Rios F, Esteller M and Sanchez-Cespedes M: Transcriptional targets of the chromatin-remodelling factor SMARCA4/BRG1 in lung cancer cells. *Hum Mol Genet* 14: 973-982, 2005.
7. Mohrmann L and Verrijzer CP: Composition and functional specificity of the SWI2/SNF2 class chromatin remodeling complexes. *Biochim Biophys Acta* 1681: 59-73, 2005.
8. Wang W, Côté J, Xue Y, Zhou S, Khavari PA, Biggar SR, Muchardt C, Kalpana GV, Goff SP, Yaniv M, *et al*: Purification and biochemical heterogeneity of the mammalian SWI-SNF complex. *EMBO J* 15: 5370-5382, 1996.
9. Phelan ML, Sif S, Narlikar GJ and Kingston RE: Reconstitution of a core chromatin remodeling complex from SWI/SNF subunits. *Mol Cell* 3: 247-253, 1999.
10. Kaeser MD, Aslanian A, Dong MQ, Yates JR III and Emerson BM: BRD7, a novel PBAF-specific SWI/SNF subunit, is required for target gene activation and repression in embryonic stem cells. *J Biol Chem* 283: 32254-32263, 2008.
11. Wang X, Nagl NG Jr, Wilsker D, Van Scoy M, Pacchione S, Yaciuk P, Dallas PB and Moran E: Two related ARID family proteins are alternative subunits of human SWI/SNF complexes. *Biochem J* 383: 319-325, 2004.
12. Chunder N, Mandal S, Basu D, Roy A, Roychoudhury S and Panda CK: Deletion mapping of chromosome 1 in early onset and late onset breast tumors - a comparative study in eastern India. *Pathol Res Pract* 199: 313-321, 2003.
13. Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, Davies H, Jones D, Lin ML, Teague J, *et al*: Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. *Nature* 469: 539-542, 2011.
14. Jones S, Li M, Parsons DW, Zhang X, Wesseling J, Kristel P, Schmidt MK, Markowitz S, Yan H, Bigner D, *et al*: Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. *Hum Mutat* 33: 100-103, 2012.
15. Zang ZJ, Cutcutache I, Poon SL, Zhang SL, McPherson JR, Tao J, Rajasegaran V, Heng HL, Deng N, Gan A, *et al*: Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. *Nat Genet* 44: 570-574, 2012.
16. Gui Y, Guo G, Huang Y, Hu X, Tang A, Gao S, Wu R, Chen C, Li X, Zhou L, *et al*: Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. *Nat Genet* 43: 875-878, 2011.
17. Agrawal N, Jiao Y, Bettegowda C, Hutfless SM, Wang Y, David S, Cheng Y, Twaddell WS, Latt NL, Shin EJ, *et al*: Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. *Cancer Discov* 2: 899-905, 2012.
18. Stroppel MM, Lata S, DelaBastide M, Montgomery EA, Wang JS, Canto MI, Macgregor-Das AM, Pai S, Morsink FH, Offerhaus GJ, *et al*: Next-generation sequencing of endoscopic biopsies identifies ARID1A as a tumor-suppressor gene in Barrett's esophagus. *Oncogene* 33: 347-357, 2014.
19. Huang J, Deng Q, Wang Q, Li KY, Dai JH, Li N, Zhu ZD, Zhou B, Liu XY, Liu RF, *et al*: Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. *Nat Genet* 44: 1117-1121, 2012.
20. Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, Nguyen HH, Aoki M, Hosono N, Kubo M, Miya F, *et al*: Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. *Nat Genet* 44: 760-764, 2012.
21. Dulak AM, Stojanov P, Peng S, Lawrence MS, Fox C, Stewart C, Bantla S, Imamura Y, Schumacher SE, Shefler E, *et al*: Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. *Nat Genet* 45: 478-486, 2013.
22. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, *et al*: Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. *Cell* 150: 1107-1120, 2012.
23. Shain AH, Giacomini CP, Matsukuma K, Karikari CA, Bashyam MD, Hidalgo M, Maitra A and Pollack JR: Convergent structural alterations define SWI/SNF chromatin remodeler as a central tumor suppressive complex in pancreatic cancer. *Proc Natl Acad Sci USA* 109: E252-E259, 2012.
24. Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J, *et al*: Australian Pancreatic Cancer Genome Initiative: Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. *Nature* 491: 399-405, 2012.
25. Cornen S, Adelaide J, Bertucci F, Finetti P, Guille A, Birnbaum DJ, Birnbaum D and Chaffanet M: Mutations and deletions of ARID1A in breast tumors. *Oncogene* 31: 4255-4256, 2012.
26. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, Bignell GR, *et al*: Oslo Breast Cancer Consortium (OSBREAC): The landscape of cancer genes and mutational processes in breast cancer. *Nature* 486: 400-404, 2012.
27. Giulino-Roth L, Wang K, MacDonald TY, Mathew S, Tam Y, Cronin MT, Palmer G, Lucena-Silva N, Pedrosa F, Pedrosa M, *et al*: Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes. *Blood* 120: 5181-5184, 2012.
28. Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, Richards KL, Dunphy CH, Choi WW, Srivastava G, *et al*: The genetic landscape of mutations in Burkitt lymphoma. *Nat Genet* 44: 1321-1325, 2012.
29. Sausen M, Leary RJ, Jones S, Wu J, Reynolds CP, Liu X, Blackford A, Parmigiani G, Diaz LA Jr, Papadopoulos N, *et al*: Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. *Nat Genet* 45: 12-17, 2013.
30. Jones S, Wang TL, Shih IeM, Mao TL, Nakayama K, Roden R, Glas R, Slamon D, Diaz LA Jr, Vogelstein B, *et al*: Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. *Science* 330: 228-231, 2010.
31. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, *et al*: ARID1A mutations in endometriosis-associated ovarian carcinomas. *N Engl J Med* 363: 1532-1543, 2010.
32. Guan B, Mao TL, Panuganti PK, Kuhn E, Kurman RJ, Maeda D, Chen E, Jeng YM, Wang TL and Shih IeM: Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. *Am J Surg Pathol* 35: 625-632, 2011.
33. Guan B, Gao M, Wu C-H, Wang T-L and Shih IeM: Functional analysis of in-frame indel ARID1A mutations reveals new regulatory mechanisms of its tumor suppressor functions. *Neoplasia* 14: 986-993, 2012.
34. Luchini C, Veronese N, Solmi M, Cho H, Kim J-H, Chou A, Gill AJ, Faraj SF, Chaux A, Netto GJ, *et al*: Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: A systematic review and meta-analysis. *Oncotarget*: Sept 8, 2015 (Epub ahead of print).
35. Guan B, Wang TL and Shih IeM: ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. *Cancer Res* 71: 6718-6727, 2011.
36. Yamamoto S, Tsuda H, Takano M, Tamai S and Matsubara O: Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations. *Mod Pathol* 25: 615-624, 2012.
37. Veras E, Mao TL, Ayhan A, Ueda S, Lai H, Hayran M, Shih IeM and Kurman RJ: Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases. *Am J Surg Pathol* 33: 844-853, 2009.
38. Wu CH, Mao TL, Vang R, Ayhan A, Wang TL, Kurman RJ and Shih IeM: Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A. *Int J Gynecol Pathol* 31: 297-303, 2012.
39. Ayhan A, Mao TL, Seckin T, Wu CH, Guan B, Ogawa H, Futagami M, Mizukami H, Yokoyama Y, Kurman RJ, *et al*: Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma. *Int J Gynecol Cancer* 22: 1310-1315, 2012.
40. Vercellini P, Crosignani P, Somigliana E, Viganò P, Buggio L, Bolis G and Fedele L: The 'incessant menstruation' hypothesis: A mechanistic ovarian cancer model with implications for prevention. *Hum Reprod* 26: 2262-2273, 2011.

41. Yamaguchi K, Mandai M, Toyokuni S, Hamanishi J, Higuchi T, Takakura K and Fujii S: Contents of endometriotic cysts, especially the high concentration of free iron, are a possible cause of carcinogenesis in the cysts through the iron-induced persistent oxidative stress. *Clin Cancer Res* 14: 32-40, 2008.
42. Guan B, Rahmanto YS, Wu R-C, Wang Y, Wang Z, Wang T-L and Shih IeM: Roles of deletion of Arid1a, a tumor suppressor, in mouse ovarian tumorigenesis. *J Natl Cancer Inst* 106: dju146, 2014.
43. Tanwar PS, Kaneko-Tarui T, Lee HJ, Zhang L and Teixeira JM: PTEN loss and HOXA10 expression are associated with ovarian endometrioid adenocarcinoma differentiation and progression. *Carcinogenesis* 34: 893-901, 2013.
44. Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, Wang TL, Glas R, Slamon D, Velculescu VE, Kuman RJ, *et al*: Frequent activating mutations of *PIK3CA* in ovarian clear cell carcinoma. *Am J Pathol* 174: 1597-1601, 2009.
45. Yamamoto S, Tsuda H, Takano M, Iwaya K, Tamai S and Matsubara O: *PIK3CA* mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma. *J Pathol* 225: 189-194, 2011.
46. Yamamoto S, Tsuda H, Takano M, Tamai S and Matsubara O: *PIK3CA* mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma. *Virchows Arch* 460: 77-87, 2012.
47. Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, *et al*: High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. *Cancer Discov* 1: 170-185, 2011.
48. Llobet D, Pallares J, Yeramian A, Santacana M, Eritja N, Velasco A, Dolcet X and Matias-Guiu X: Molecular pathology of endometrial carcinoma: Practical aspects from the diagnostic and therapeutic viewpoints. *J Clin Pathol* 62: 777-785, 2009.
49. Wiegand KC, Lee AF, Al-Agha OM, Chow C, Kalloger SE, Scott DW, Steidl C, Wiseman SM, Gascoyne RD, Gilks B, *et al*: Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. *J Pathol* 224: 328-333, 2011.
50. McConechy MK, Ding J, Cheang MC, Wiegand KC, Senz J, Tone AA, Yang W, Prentice LM, Tse K, Zeng T, *et al*: Use of mutation profiles to refine the classification of endometrial carcinomas. *J Pathol* 228: 20-30, 2012.
51. Liang H, Cheung LW, Li J, Ju Z, Yu S, Stemke-Hale K, Dogruluk T, Lu Y, Liu X, Gu C, *et al*: Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. *Genome Res* 22: 2120-2129, 2012.
52. Bosse T, ter Haar NT, Seeber LM, v Diest PJ, Hes FJ, Vasen HF, Nout RA, Creutzberg CL, Morreau H and Smit VT: Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer. *Mod Pathol* 26: 1525-1535, 2013.
53. Mao TL, Ardighieri L, Ayhan A, Kuo KT, Wu CH, Wang TL and Shih IeM: Loss of ARID1A expression correlates with stages of tumor progression in uterine endometrioid carcinoma. *Am J Surg Pathol* 37: 1342-1348, 2013.
54. Hoang LN, McConechy MK, Meng B, McIntyre JB, Ewanowich C, Gilks CB, Huntsman DG, Köbel M and Lee CH: Targeted mutation analysis of endometrial clear cell carcinoma. *Histopathology* 66: 664-674, 2015.
55. Fadare O, Renshaw IL and Liang SX: Does the loss of ARID1A (BAF-250a) expression in endometrial clear cell carcinomas have any clinicopathologic significance? A pilot assessment. *J Cancer* 3: 129-136, 2012.
56. Zhang ZM, Xiao S, Sun GY, Liu YP, Zhang FH, Yang HF, Li J, Qiu HB, Liu Y, Zhang C, *et al*: The clinicopathologic significance of the loss of BAF250a (ARID1A) expression in endometrial carcinoma. *Int J Gynecol Cancer* 24: 534-540, 2014.
57. Fadare O, Gwin K, Desouki MM, Crispens MA, Jones HW III, Khabele D, Liang SX, Zheng W, Mohammed K, Hecht JL, *et al*: The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium. *Mod Pathol* 26: 1101-1110, 2013.
58. van Nagell JR Jr and Hoff JT: Transvaginal ultrasonography in ovarian cancer screening: Current perspectives. *Int J Womens Health* 6: 25-33, 2013.
59. Takano M, Kikuchi Y, Kudoh K, Goto T, Furuya K, Kikuchi R, Kita T, Fujiwara K, Shiozawa T and Aoki D: Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: A report of six cases. *Int J Clin Oncol* 16: 605-609, 2011.
60. Scott JD and Williams RM: Chemistry and biology of the tetrahydroisoquinoline antitumor antibiotics. *Chem Rev* 102: 1669-1730, 2002.
61. Kwan JC and Luesch H: Weapons in disguise - activating mechanisms and protecting group chemistry in nature. *Chemistry* 16: 13020-13029, 2010.
62. Rahman M, Nakayama K, Ishibashi T, Ishikawa M, Rahman MT, Katagiri H, Katagiri A, Iida K, Kikuchi Y and Miyazaki K: A case of stage III c ovarian clear cell carcinoma: The role for predictive biomarkers and targeted therapies. *Int J Mol Sci* 14: 6067-6073, 2013.
63. Bitler BG, Aird KM, Garipov A, Li H, Amatangelo M, Kossenkov AV, Schultz DC, Liu Q, Shih IeM, Conejo-Garcia JR, *et al*: Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. *Nat Med* 1: 231-238, 2015.
64. Helming KC, Wang X, Wilson BG, Vazquez F, Haswell JR, Manchester HE, Kim Y, Kryukov GV, Ghandi M, Aguirre AJ, *et al*: ARID1B is a specific vulnerability in ARID1A-mutant cancers. *Nat Med* 20: 251-254, 2014.
65. Park JH, Lee C, Suh JH, Chae JY, Kim HW and Moon KC: Decreased ARID1A expression correlates with poor prognosis of clear cell renal cell carcinoma. *Hum Pathol* 46: 454-460, 2015.
66. Wei XL, Wang DS, Xi SY, Wu WJ, Chen DL, Zeng ZL, Wang RY, Huang YX, Jin Y, Wang F, *et al*: Clinicopathologic and prognostic relevance of ARID1A protein loss in colorectal cancer. *World J Gastroenterol* 20: 18404-18412, 2014.
67. Faraj SF, Chaux A, Gonzalez-Roibon N, Munari E, Ellis C, Driscoll T, Schoenberg MP, Bivalacqua TJ, Shih IeM and Netto GJ: ARID1A immunohistochemistry improves outcome prediction in invasive urothelial carcinoma of urinary bladder. *Hum Pathol* 45: 2233-2239, 2014.
68. Wiegand KC, Sy K, Kalloger SE, Li-Chang H, Woods R, Kumar A, Streutker CJ, Hafezi-Bakhtiari S, Zhou C, Lim HJ, *et al*: ARID1A/BAF250a as a prognostic marker for gastric carcinoma: A study of 2 cohorts. *Hum Pathol* 45: 1258-1268, 2014.
69. Yokoyama Y, Matsushita Y, Shigetou T, Futagami M and Mizunuma H: Decreased ARID1A expression is correlated with chemoresistance in epithelial ovarian cancer. *J Gynecol Oncol* 25: 58-63, 2014.
70. Itamochi H, Oumi N, Oishi T, Shoji T, Fujiwara H, Sugiyama T, Suzuki M, Kigawa J and Harada T: Loss of ARID1A expression is associated with poor prognosis in patients with stage I/II clear cell carcinoma of the ovary. *Int J Clin Oncol* 20: 967-973, 2015.